ClinicalTrials.gg
CompletedNCT00965094Updated Aug 15, 2014Results posted

Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients

A Phase 4 interventional study of Everolimus and Tacrolimus (FK506) in Chronic Renal Failure, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in Israel. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-08-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 40 studies in Kidney Failure, Chronic with a site in Israel — 3 open to participants now, 5 under way, 2 of them phase 3. Kidney Failure, Chronic · Israel.

Enrollment
22nd of 29
36 · median 160
Started
2009
with 1 other
Phase 4
3 of 40
none open now
Registered
14th of 40
by date
Lead sponsor
2 of 40
Novartis Pharmaceuticals

Among the 40 studies in Kidney Failure, Chronic with a site in Israel, this one is the 22nd largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2009, is one of 3 in phase 4, and was the 14th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

3 of the 40 studies in Kidney Failure, Chronic with a site in Israel are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Kidney Failure, Chronic with a site in Israel, or all of them as a file.
02

Study summary

The primary objective of this trial is to show non-inferiority of a CNI-free regimen with respect to the renal function at Month 9 post Tx assessed by glomerular filtration rate - Nankivell method - as compared to the standard CNI-based regimen in de novo renal transplant patients.

03

Conditions studied

  • Chronic Renal Failure
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recipients of de novo cadaveric, living unrelated or living related kidney transplants
  • Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at screening, and are required to practice an approved method of for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility.
  • Patients who are willing and able to participate in the study and from whom written has been obtained.

Exclusion criteria

Exclusion criteria:

  • More than one previous renal transplantation
  • Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney
  • Donor age: \< 5 years or > 65 years
  • Graft loss due to immunological reasons in the first year after transplantation (in case of secondary transplantation)
  • Patients who had received an drug within 4 weeks of the baseline period
  • Patients who are recipients of A-B-O incompatible transplants or T cell cross-match positive transplants
  • Patients with already existing antibodies against the HLA-type of the receiving transplant
  • Patients with any known to Simulect®, Certican®, mycophenolic acid, Prograf®, other drugs similar to Certican® (e.g., macrolides), or other components of the formulations.
  • Patients who have received an investigational drug within four weeks prior to study entry (Baseline visit 1)
  • Patients with thrombocytopenia ( \< 75,000/mm³), or an of \< 1,500/mm³ or leucopenia (leucocytes \< 2,500/mm³), or \< 6 g/dL
  • Patients with preexisting lung disease (alveolitis, fibrosis) Patients with symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, who are unlikely to comply with the study requirements, or who are unable to give
  • Patients with a history of during the last five years, except squamous or basal cell carcinoma of the skin
  • Patients who are positive or surface antigen positive or virus positive. Recipients of organs from donors who test positive for Hepatitis B surface antigen or Hepatitis C are excluded.
  • Evidence of severe liver disease (incl. abnormal liver enzyme profile, i.e. , ALT or total > 3 times UNL)
  • Females of who are planning to become pregnant, who are pregnant or lactating, and/or who are unwilling to use effective means of (see also section 8.2)
  • Presence of a infection requiring continued therapy, severe diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus that in the opinion of the investigator would interfere with the appropriate conduct of the study
  • Evidence of drug or alcohol abuse
  • Patients receiving drugs known to interact with Tacrolimus and/or everolimus according to the list provided in Appendix 3 to this protocol.
  • Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Everolimus

    At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 \[Month 3 (+1 week) after transplantation\], eligible patients were randomized, using living and cadaveric donation as stratum. Patients were switched to the CNI-free regimen. Everolimus was added to the patients immunosuppressive regimen and tacrolimus was removed successively.

    Drug: Everolimus · Drug: Basiliximab · Drug: Enteric Coated Mycophenolate Sodium (EC-MPS) · Drug: Corticosteroids

  • Active comparator
    Reference Therapy

    At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 \[Month 3 (+1 week) after transplantation\], eligible patients were randomized, using living and cadaveric donation as stratum. Patients continued on the prior immunosuppressive regimen consisting of MPA + tacrolimus with corticosteroids.

    Drug: Tacrolimus (FK506) · Drug: Basiliximab · Drug: Enteric Coated Mycophenolate Sodium (EC-MPS) · Drug: Corticosteroids

Interventions

  • One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)

    Also known as: Certican

  • Capsules 0.5 mg, 1 mg. Dosing according to blood level.

    Also known as: Prograf

  • One vial containing 20 mg lyophilisate. 2 x 20 mg \[day 0 (2 hrs prior to Tx) and day 4 post Tx\] to be applied as 10 sec. bolus injection, i.v.

    Also known as: Simulect

  • One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)

    Also known as: Myfortic

  • DrugCorticosteroids

    Used according to Israeli standards. A minimum dose of 5mg \[prednisone, or equivalent, was used throughout the study period.

06

What researchers measure

Primary outcomes

  1. Renal Function Assessed as Glomerula Filtration Rate (GFR) - Nankivell Method - 9 Months After Renal Transplantation (LOCF)

    The glomerular filtration rate (GFR) is the best clinical estimate of renal function in health and disease, and correlates well with the clinical severity of renal function disturbances. The GFR, calculated according to the Nankivell formula, was used as the primary outcome measure in this study. This equation has been validated in renal transplant patients against the true GFR measured by a radionuclide method and has been confirmed as a very accurate method to calculate the GFR in this specific population (Gaspari et al., 2004)GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)² + C Scr = serum creatinine concentration expressed in mmol/L. BW = body weight in kg, Surea = serum urea in mmol/L and Height is expressed in meters.The Last Observation Carried Forward (LOCF) imputation technique was used for this analysis.

    Time frame: 9 months

Secondary outcomes

  1. Assessment of GFR by the Cockcroft-Gault Method (LOCF)

    the GFR was also calculated using the Cockcroft-Gault method (Cockcroft and Gault 1976) and the Modification of Diet in Renal Disease (MDRD) method (Levey et al., 1999, Rodrigo et al., 2003; Pierrat et al., 2003).Cockcroft-Gault formula For men: GFR= (140-Age)X Body Weight\[kg\]/72X Serum Creatinine\[mg/dl\] For women: GFR= 0,85x(140-Age) x Body Weight\[kg\]/72x Serum Creatinine \[mg/dl\] The Last Observation Carried Forward (LOCF) imputation technique was used for this analysis.

    Time frame: 9 months

  2. Participants Who Had Occurrence of Biopsy Proven Acute Rejection, Graft Loss or Death.

    Biopsy-proven acute rejection was defined as a biopsy gradeed IA, IB, IIA, IIB, or III. The allograft was presumed to be lost if the patient started dialysis and was not able to subsequently be removed from dialysis. If the patient underwent a graft nephrectomy, then the day of nephrectomy was the day of graft loss.

    Time frame: 9 months

  3. Participants Who Had Occurrence of Treatment Failure.

    Treatment failure was defined as a composite endpoint of biopsy-proven acute rejection, graft loss, death, loss to follow up, discontinuation due to lack of efficacy or toxicity or conversion to another regimen.

    Time frame: 9 months

  4. Change in Renal Function (Creatinine Slope)

    X(slope)=(1/value of creatinine).

    Time frame: 3 months, 5 months, 7 months, 9 months

07

Results

Posted Aug 15, 2014

Participant flow

Participant flow — Overall Study
MilestoneEverolimusReference Therapy
Started1917
Completed1416
Not completed51
Withdrew: Adverse event50
Withdrew: Lost to follow-up01

Outcome measures

PrimaryRenal Function Assessed as Glomerula Filtration Rate (GFR) - Nankivell Method - 9 Months After Renal Transplantation (LOCF)

The glomerular filtration rate (GFR) is the best clinical estimate of renal function in health and disease, and correlates well with the clinical severity of renal function disturbances. The GFR, calculated according to the Nankivell formula, was used as the primary outcome measure in this study. This equation has been validated in renal transplant patients against the true GFR measured by a radionuclide method and has been confirmed as a very accurate method to calculate the GFR in this specific population (Gaspari et al., 2004)GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)² + C Scr = serum creatinine concentration expressed in mmol/L. BW = body weight in kg, Surea = serum urea in mmol/L and Height is expressed in meters.The Last Observation Carried Forward (LOCF) imputation technique was used for this analysis.

Time frame:
9 months
Reported as:
Mean · mL/min/1.73m^2
Renal Function Assessed as Glomerula Filtration Rate (GFR) - Nankivell Method - 9 Months After Renal Transplantation (LOCF)
mL/min/1.73m^2EverolimusReference Therapy
Renal Function Assessed as Glomerula Filtration Rate (GFR) - Nankivell Method - 9 Months After Renal Transplantation (LOCF)15.0 ± 10.316.6 ± 7.0
SecondaryAssessment of GFR by the Cockcroft-Gault Method (LOCF)

the GFR was also calculated using the Cockcroft-Gault method (Cockcroft and Gault 1976) and the Modification of Diet in Renal Disease (MDRD) method (Levey et al., 1999, Rodrigo et al., 2003; Pierrat et al., 2003).Cockcroft-Gault formula For men: GFR= (140-Age)X Body Weight\[kg\]/72X Serum Creatinine\[mg/dl\] For women: GFR= 0,85x(140-Age) x Body Weight\[kg\]/72x Serum Creatinine \[mg/dl\] The Last Observation Carried Forward (LOCF) imputation technique was used for this analysis.

Time frame:
9 months
Reported as:
Mean · mL/min
Assessment of GFR by the Cockcroft-Gault Method (LOCF)
mL/minEverolimusReference Therapy
Assessment of GFR by the Cockcroft-Gault Method (LOCF)72.6 ± 18.972.7 ± 20.5
SecondaryParticipants Who Had Occurrence of Biopsy Proven Acute Rejection, Graft Loss or Death.

Biopsy-proven acute rejection was defined as a biopsy gradeed IA, IB, IIA, IIB, or III. The allograft was presumed to be lost if the patient started dialysis and was not able to subsequently be removed from dialysis. If the patient underwent a graft nephrectomy, then the day of nephrectomy was the day of graft loss.

Time frame:
9 months
Reported as:
Number · Participants
Participants Who Had Occurrence of Biopsy Proven Acute Rejection, Graft Loss or Death.
ParticipantsEverolimusReference Therapy
No1414
Yes11
SecondaryParticipants Who Had Occurrence of Treatment Failure.

Treatment failure was defined as a composite endpoint of biopsy-proven acute rejection, graft loss, death, loss to follow up, discontinuation due to lack of efficacy or toxicity or conversion to another regimen.

Time frame:
9 months
Reported as:
Number · Participants
Participants Who Had Occurrence of Treatment Failure.
ParticipantsEverolimusReference Therapy
No1014
Yes51
SecondaryChange in Renal Function (Creatinine Slope)

X(slope)=(1/value of creatinine).

Time frame:
3 months, 5 months, 7 months, 9 months
Reported as:
Mean · mg/dl per month
Change in Renal Function (Creatinine Slope)
mg/dl per monthEverolimusReference Therapy
(ITT) Baseline 2: Month 3 N=15, 150.7 ± 0.10.7 ± 0.2
(ITT) Month 3 (1st week) N=15, 40.7 ± 0.20.8 ± 0.1
(ITT) Month 3 (2nd week) N=15, 40.8 ± 0.10.9 ± 0.2
(ITT) Month 3 (3rd week) N=13, 20.7 ± 0.10.9 ± 0.2
(ITT) Month 3 (4th week) N=12, 0*0.8 ± 0.1NA ± NA
(ITT) Month 5 N=14, 150.8 ± 0.20.7 ± 0.2
(ITT) Month 7 N=14, 140.7 ± 0.20.7 ± 0.2
(ITT) Month 9 N=11, 150.8 ± 0.20.8 ± 0.2
(PP) Baseline 2: Month 3 N=11, 150.7 ± 0.10.7 ± 0.2
(PP) Month 3 (first week) N=11, 40.7 ± 0.20.8 ± 0.1
(PP) Month 3 (second week) N=11, 40.8 ± 0.10.9 ± 0.2
(PP) Month 3 (third week) N=10, 20.7 ± 0.10.9 ± 0.2
(PP) Month 3 (fourth week) N=9, 0*0.8 ± 0.1NA ± NA
(PP) Month 5 N=11, 150.8 ± 0.20.7 ± 0.2
(PP) Month 7 N=11, 140.8 ± 0.20.7 ± 0.2
(PP) Month 9 N=11, 150.8 ± 0.20.8 ± 0.2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus—7/19 (36.8%)19/19 (100%)
Reference Therapy—7/17 (41.2%)15/17 (88.2%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventEverolimusReference Therapy
Blood creatinine increasedInvestigations1/193/17
Transplant rejectionImmune system disorders2/191/17
DiarrhoeaGastrointestinal disorders0/191/17
VomitingGastrointestinal disorders0/191/17
PyrexiaGeneral disorders0/191/17
Urinary tract infectionInfections and infestations1/191/17
HypomagnesaemiaMetabolism and nutrition disorders0/191/17
Abdominal painGastrointestinal disorders1/190/17
Gastroenteritis viralInfections and infestations1/190/17
Herpes zosterInfections and infestations1/190/17
Most frequent other events
Showing 10 of 65
Most frequent other events
EventEverolimusReference Therapy
HypomagnesaemiaMetabolism and nutrition disorders0/197/17
ProteinuriaRenal and urinary disorders6/190/17
LeukopeniaBlood and lymphatic system disorders5/191/17
Aphthous stomatitisGastrointestinal disorders5/190/17
Blood lactate dehydrogenaseInvestigations4/191/17
Diabetes mellitusEndocrine disorders2/193/17
Blood creatinine increasedInvestigations2/193/17
DysuriaRenal and urinary disorders0/193/17
AnaemiaBlood and lymphatic system disorders3/191/17
Abdominal painGastrointestinal disorders3/190/17

Baseline characteristics

Enrolled patient population included all patients who signed an informed consent regardless whether renal transplanation as performed or not.

Age, Continuous
Age, Continuous(Years)EverolimusReference TherapyTotal
Mean53.1 ± 13.449.6 ± 12.151.4 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)EverolimusReference TherapyTotal
Female538
Male141428
08

Study locations

3 sites
  • Novartis Investigative Site
    Haifa, 31096, Israel
  • Novartis Investigative Site
    Petach Tikva, 49100, Israel
  • Novartis Investigative Site
    Tel-Aviv, 64239, Israel
09

References and documents

Publications

  • Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation. 2009 Aug 15;88(3):421-8. doi: 10.1097/TP.0b013e3181af1df6. PubMed 19667948 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2009
First posted
Aug 25, 2009
Start
Dec 2009
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Aug 15, 2014
Last update
Aug 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00965094
Responsible party
Sponsor
First posted
Aug 25, 2009
Start date
Dec 2009
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Aug 15, 2014
Last update
Aug 15, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion